LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming December 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Synopsys, Inc. ("Synopsys†or the "Company†) (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, inclusive (the "Class Period†). IF YOU SUFFERED A LOSS ON YOUR SYNOPSYS INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS. ...

Zimmer Biomet, the maker of knee and hip replacements, missed on quarterly sales estimates and lowered the top end of its outlook for full-year organic revenue growth. ...

Accessibility StatementSkip Navigation It is a division of Datatec Limited, listed on the Johannesburg Stock Exchange, with revenues of over $4.6 billion. For more information visit https://us.logicalis.com TROY, Mich., Nov. 5, 2025 /PRNewswire/ --Â Logicalis US, the leading global technology service provider, has been named Managed Services Partner of the Year for the Americas at Cisco Partner Summit 2025. Cisco Partner Awards recognize top-performing partners demonstrating service excellence and innovatio ...

Accessibility StatementSkip Navigation TORONTO, Nov. 5, 2025 /PRNewswire/ - EQB Inc. (TSX: EQB) will report its fourth quarter and fiscal 2025 financial results after market close on December 3, 2025, and will host an earnings conference call on December 4, 2025, at 10:30 a.m. ET. EQB's Chadwick Westlake, President and Chief Executive Officer, Anilisa Sainani, Chief Financial Officer, and Marlene Lenarduzzi, Chief Risk Officer, will host the listen-only conference call and webcast. The details of the call/w ...

Analyst’s Disclosure:I/we have a beneficial long position in the shares of SNDX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers a ...

About this content About Sean Mason Sean Mason is a Senior Journalist at Proactive, having researched and written about Canadian and US equities for 20 years. Sean graduated from the University of Toronto with a BA in history and economics and has also passed the Canadian Securities Course. He previously worked at Investors Digest of Canada, Stockhouse, and SmallCapPower.com. Read more About the publisher Proactive financial news and online broadcast teams provide fast, accessible, informative and action ...

U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points on Wednesday.Shares of Johnson Controls International PLC (NYSE:JCI) rose sharply during Wednesday's session after the company reported fourth-quarter results that topped analyst estimates on both earnings and revenue.The company reported fourth-quarter adjusted earnings per share of $1.26, beating the analyst consensus estimate of $1.20. Quarterly revenue came in at $6.44 billion, topping the Street's $6.32 billion forecast.Joh ...

Key Takeaways Bio-Techne posted Q1 EPS of 42 cents, matching estimates and flat year over year.TECH revenues fell 1% to $286.6 million, missing expectations and triggering a 7.5% stock drop. TECH's gross and operating margins expanded, supported by lower costs and stable segment performance. Bio-Techne Corporation (TECH) reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of 42 cents, which matched the Zacks Consensus Estimate. The bottom line remained flat on a year-over-year basis. The qu ...

Key Takeaways SMP posted Q3 EPS of $1.36, above estimates and up from $1.28 a year earlier.Revenues rose to $499 million, driven by strong Temperature Control segment sales.2025 sales growth guidance raised to low-to-mid 20s%, with higher EBITDA margin outlook.Standard Motor Products (SMP) posted third-quarter 2025 adjusted earnings per share (EPS) of $1.36, which surpassed the Zacks Consensus Estimate of $1.14 and rose from $1.28 reported in the prior-year quarter.Total revenues rose to $499 million from $ ...

Key Takeaways Exelixis' Q3 earnings of $0.78 per share topped estimates and rose from $0.47 a year ago.Revenues grew 10.8% to $598M, driven by higher Cabometyx sales and strong product demand.EXEL narrows 2025 revenue outlook to $2.30-$2.35B and expands its stock repurchase program.Exelixis, Inc. (EXEL) reported better-than-expected results for the third quarter of 2025.Adjusted earnings of 78 cents per share beat the Zacks Consensus Estimate of 68 cents. The company registered adjusted earnings of 47 cents ...